A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial

Recurrent ventricular tachycardia (VT) in patients with prior myocardial infarction is associated with adverse quality of life and clinical outcomes, despite the presence of implanted defibrillators (ICDs). Suppression of recurrent VT can be accomplished with antiarrhythmic drug therapy or catheter...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2024-08, Vol.274, p.1-10
Hauptverfasser:	Sapp, John L., Tang, Anthony S.L., Parkash, Ratika, Stevenson, William G., Healey, Jeff S., Wells, George
Format:	Artikel
Sprache:	eng
Schlagworte:	Ablation Amiodarone Amiodarone - therapeutic use Anti-Arrhythmia Agents - therapeutic use Antiarrhythmics Beta blockers Cardiac arrhythmia Cardiomyopathies - complications Cardiomyopathies - therapy Cardiomyopathy Cardiovascular diseases Catheter Ablation - methods Catheters Clinical medicine Clinical trials Combined Modality Therapy Defibrillators, Implantable Drug therapy Female Heart attacks Heart diseases Heart failure Humans Ischemia Male Medical instruments Middle Aged Mortality Myocardial infarction Myocardial Ischemia - complications Quality of life Radiofrequency ablation Randomization Signs and symptoms Sotalol - therapeutic use Tachycardia Tachycardia, Ventricular - therapy Treatment Outcome Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!